We are committed to building the next-generation of TRP channel targeted first-in-class medicines.
As part of our value-creation strategy, the company actively seeks strategic partnerships to broaden the application of our platform and to rapidly advance our high-value product candidates. The scope of the opportunity extends beyond our growing and deep pipeline. Unexploited regions of the TRP superfamily of targets, are now available for drug development using the Algomedix rational drug discovery approach. We welcome the interest from pharmaceutical and biotechnology companies.
We are also actively seeking potential collaboration or licensing opportunities that would complement our existing portfolio. We are interested in building alliances that will enable us to realize our long-term vision of transforming lives with safer, more effective therapies.